Taken together, MALAT1 and GAS5 were positively correlated with NASH grade and/or fibrosis, and thus may be candidate biomarkers for severe NAFLD (such as NASH, fibrosis) and may open up new frontiers for NAFLD drug development. Here, MALAT1 is linked to metabolic dysfunction-associated steatohepatitis.